A multicenter, prospective, real-world study on the ShenSongYangXin Capsules in the reduction of composite events of sudden cardiac death in patients with organic heart disease and ventricular arrhythmia - ACCEPT

Start Date20 May 2024

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

100 Clinical Results associated with ShenSongYangXin

100 Translational Medicine associated with ShenSongYangXin

100 Patents (Medical) associated with ShenSongYangXin

Literatures (Medical) associated with ShenSongYangXin

21 Oct 2024·European Heart Journal

Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial

Article

Author: Zhang, Menghe ; Liu, Yu ; Tang, Yanhong ; Chen, Manhua ; Shuai, Wei ; Huang, He ; Qu, Xiufen ; Yang, Hao ; Huang, Congxin ; Jiang, Chenyang ; Mu, Bin ; Zheng, Wenqing ; Liu, Fan ; Yu, Bo ; Ouyang, Feifan ; Jia, Zhenhua ; Yao, Chen

AbstractBackground and AimsDespite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF.MethodsA multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted at 66 centres in China among 920 patients with persistent AF undergoing first ablation. Participants were randomized to oral SSYX, 1.6 g (.4 g/granule) thrice daily (n = 460), or matched placebo (n = 460) for 12 months. The primary endpoint was recurrent atrial tachyarrhythmias lasting for ≥30 s following a blanking period of 3 months. Secondary endpoints included time to first documented atrial tachyarrhythmias, AF burden, cardioversion, stroke/systemic embolism, changes in echocardiographic parameters, and quality-of-life (QoL) score. Analyses were performed according to the intention-to-treat principle.ResultsA total of 920 patients underwent randomization (460 assigned to SSYX group and 460 assigned to placebo group). During the follow-up of 12 months, patients assigned to SSYX had a higher event-free rate from recurrent atrial tachyarrhythmias when compared with the placebo group (12-month Kaplan–Meier event-free rate estimates, 85.5% and 77.7%, respectively; hazard ratio, .6; 95% confidence interval .4–.8; P = .001). Patients assigned to receive SSYX had a better QoL score at 12 months compared to those randomized to placebo. There was no significant difference in the incidence of serious adverse events between the two groups.ConclusionsTreatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.

01 Aug 2024·Heliyon

Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications

Review

Author: Han, Ningxin ; Hou, Bin ; Lu, Xuan ; Li, Hongrong ; Xin, Jingjing ; He, Yanling ; Wang, Tongxing ; Wei, Cong ; Jia, Zhenhua ; Zhang, Dan ; Wang, Xiaoqi

As a common cardiovascular disease (CVD), Arrhythmia refers to any abnormality in the origin, frequency, rhythm, conduction velocity, timing, pathway, sequence, or other aspect of cardiac impulses, and it is one of the common cardiovascular diseases in clinical practice. At present, various ion channel blockers are used for treatment of arrhythmia that include Na⁺ ion channel blockers, K⁺ ion channel blockers and Ca²⁺ ion channel blockers. While these drugs offer benefits, they have led to a gradual increase in drug-related adverse reactions across various systems. As a result, the quest for safe and effective antiarrhythmic drugs is pressing. Recent years have seen some advancements in the treatment of ventricular arrhythmias using traditional Chinese medicine(TCM). The theory of Luobing in TCM has proposed a new drug intervention strategy of "fast and slow treatment, integrated regulation" leading to a shift in mindset from "antiarrhythmic" to "rhythm-regulating". Guided by this theory, the development of Shen Song Yang Xin Capsules (SSYX) has involved various Chinese medicinal ingredients that comprehensively regulate the myocardial electrophysiological mechanism, exerting antiarrhythmic effects on multiple ion channels and non-ion channels. Similarly, in clinical studies, evidence-based research has confirmed that SSYX combined with conventional antiarrhythmic drugs can more effectively reduce the occurrence of arrhythmias. Therefore, this article provides a comprehensive review of the composition and mechanisms of action, pharmacological components, network pharmacology analysis, and clinical applications of SSYX guided by the theory of Luobing, aiming to offer valuable insights for improved clinical management of arrhythmias and related research.

01 Jul 2022·Phytomedicine

Shensong Yangxin attenuates metabolic syndrome-induced atrial fibrillation via inhibition of ferroportin-mediated intracellular iron overload

Article

Author: Shuai, Wei ; Kong, Bin ; Zhang, Jing-Jing ; Yang, Hong-Jie ; Huang, He

BACKGROUNDShensong Yangxin (SSYX) is a traditional Chinese medicine been widely used clinically to treat various arrhythmias including atrial fibrillation (AF). However, the role and precise mechanism of SSYX in MS-induced AF have not yet been elucidated.PURPOSETo elucidate the protective effects of SSYX on MS-induced AF and its possible mechanisms of action.METHODSMale Wistar rats (180-220 g) were fed a 16-week high-carbohydrate, high-fat (HCHF) diet together with 25% fructose in drinking water to produce a MS model. Low-concentration (SSYX-L, 0.4 g/kg) and high-concentration (SSYX-H, 0.8 g/kg) of SSYX were given by daily gavage 8-weeks following HCHF diet for 8-weeks. In vivo electrophysiological study, histological analysis, RNA-sequence (RNA-Seq) and gene ontology (GO) analysis, qRT-PCR and western blot were performed.RESULTSBoth low-concentration and high-concentration of SSYX could inhibit MS-induced AF susceptibility, electrical remodeling and structural remodeling. Results from RNA-sequence analysis revealed intracellular iron homeostasis mediated the protective effect of SSYX against MS. In vivo and in vitro experiments both demonstrated that SSYX up-regulated ferroportin (Fpn) expression and ameliorated intracellular iron overload induced by MS. To verified whether Fpn is the target of SSYX and intracellular iron overload mediated the protective effect of SSYX against MS, adeno-associated virus type 9 (AAV9) delivery system was used. Knocking down Fpn (AAV9-shFpn) markedly aggravated the reactive oxygen species (ROS) production, electrical remodeling and atrial fibrosis induced by MS, leading to a further increase of AF susceptibility induced by MS.CONCLUSIONOur study demonstrated for the first time that SSYX reduced AF susceptibility, inhibited electrical remodeling and structural remodeling via up-regulating Fpn, decreasing intracellular iron overload and reducing ROS production. These results suggest that SSYX might be a potential therapeutic agent for the treatment of MS-induced AF.

News (Medical) associated with ShenSongYangXin

13 Oct 2023

·www.prnewswire.com

Yiling Pharmaceutical's Shensong Yangxin Capsules Have Obtained Registration in Nigeria--Study Has Shown that It Significantly Improves the Prognosis of Patients After Radiofrequency Ablation

SHIJIAZHUANG, China, Oct. 13, 2023 /PRNewswire/ -- Recently, the National Agency for Food and Drug Administration and Control (NAFDAC) of Nigeria disclosed that the innovative patented traditional Chinese medicine (TCM), Shensong Yangxin Capsules, developed and produced by Yiling Pharmaceutical, has been granted registration in Nigeria under the category of "Herbal and Natural Medicines". Shensong Yangxin Capsules can significantly alleviate clinical symptoms such as palpitations, shortness of breath, fatigue, insomnia, and dreaminess. In August of this year, at the European Society of Cardiology Congress, a top-tier international academic conference in the field of cardiovascular medicine, the latest study results from Prof. He Huang's team at Wuhan University People's Hospital in China were disclosed. The results showed that the addition of Shensong Yangxin Capsules to standard of care could reduce the risk of atrial fibrillation recurrence within one year by about 40%, significantly improve patients' health-related Quality of life (QoL) scores and demonstrate excellent safety. This study provides a brand new treatment strategy for the prognosis of atrial fibrillation patients after radiofrequency ablation. A number of evidence-based medical studies have confirmed that Shensong Yangxin Capsules can effectively treat fast arrhythmia such as premature beats and paroxysmal atrial fibrillation; increase the slow heart rate to treat slow arrhythmia; and effectively treat complex arrhythmia such as heart failure with premature beats and sinus bradycardia with premature ventricular beats, filling the gap of drugs for both tachyarrhythmia and bradycardia at home and abroad. The "Construction of Traditional Chinese Medicine Collateral Theory and Its Guidance on Preventing and Treating Microvascular Lesions" project, which includes important studies related to Shensong Yangxin Capsules, was awarded the sole First Prize for National Science and Technology Progress in the field of life sciences in 2019. As of now, Yiling Pharmaceutical has received approval for six innovative patented traditional Chinese medicines to enter Nigeria, including Lianhua Qingwen Capsules, Tongxinluo Capsules, Qili Qiangxin Capsules, Bazi Bushen Capsules, Lianhua Qingke Tablets, and Shensong Yangxin Capsules. SOURCE Yiling Pharma

Drug Approval

100 Deals associated with ShenSongYangXin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	KE	Shijiazhuang Yiling Pharmaceutical Co., Ltd.	27 Jun 2023
Cerebrovascular Disorders	KE	Shijiazhuang Yiling Pharmaceutical Co., Ltd.	27 Jun 2023
Chronic heart failure	KE	Shijiazhuang Yiling Pharmaceutical Co., Ltd.	27 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2014	Not Applicable	Maintenance	-	Shensongyangxin Capsule	lxrcfqzfwe(xhttfcvphd) = zckexlqjiq qhocmokcuk (yzsmiqzwcr, 7.1) View more	Positive	11 Nov 2014
				Shensongyangxin Capsule	lxrcfqzfwe(xhttfcvphd) = qijaujmyqu qhocmokcuk (yzsmiqzwcr, 5.8) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

ShenSongYangXin

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation